公开(公告)号：US08715598B2

公开(公告)日：2014-05-06

申请号：US13441803

申请日：2012-04-06

申请人： Eva Kabai ,  Josue M. Moreno Bermudez ,  Richard Henkelmann ,  Andreas Türler

发明人： Eva Kabai ,  Josue M. Moreno Bermudez ,  Richard Henkelmann ,  Andreas Türler

IPC分类号： C01F13/00

CPC分类号： C22B60/00 ,  C22B3/002 ,  C22B13/04 ,  C22B26/20 ,  G21G1/001 ,  G21G2001/0094 ,  Y02P10/234

摘要： The invention is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225Ac. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.

摘要翻译： 本发明涉及一种用于纯化镭（特别是226Ra）的方法，用于使用提取色谱从化学上类似的元素如Ba，Sr和Pb分离用于从可用的放射源制备基本上纯的225Ac产物的目标制备 从所需的Ra; 其中所述提取色谱法具有基于冠醚的萃取剂体系。 本发明涉及一种用于回收226Ra的方法，用于在分离产生的225Ac之后，用加速质子（p，2n）照射的镭源进行225Ac生产的目标制备。 在该方法中，使用上述提取色谱和阳离子交换层析的组合。 得到的226Ra基本上不含由Ag，Al，As，Be，Bi，Ca，Cd，Co，Cr，Cu，Fe，Ga，K，Li，Mg，Mn，Na，Ni，Pb组成的以下化学污染物 ，Sr，V，Zn和Ba。

公开(公告)号：US08153087B2

公开(公告)日：2012-04-10

申请号：US12398346

申请日：2009-03-05

申请人： Eva Kabai ,  Josue Manuel Moreno Bermudez ,  Richard Henkelmann ,  Andreas Turler

发明人： Eva Kabai ,  Josue Manuel Moreno Bermudez ,  Richard Henkelmann ,  Andreas Turler

IPC分类号： C01F13/00

CPC分类号： C22B60/00 ,  C22B3/002 ,  C22B13/04 ,  C22B26/20 ,  G21G1/001 ,  G21G2001/0094 ,  Y02P10/234

摘要： The present application is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is further related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225AC. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.

摘要翻译： 本申请涉及用于纯化镭（特别是226Ra）的方法，用于使用提取色谱法将化学上类似的元素如Ba，Sr和 Pb从所需的Ra; 其中所述提取色谱法具有基于冠醚的萃取剂体系。 本发明进一步涉及一种用于回收226Ra的方法，用于在分离生成的225AC之后，用加速质子（p，2n）照射的镭源的225Ac生产的目标制备。 在该方法中，使用上述提取色谱和阳离子交换层析的组合。 得到的226Ra基本上不含由Ag，Al，As，Be，Bi，Ca，Cd，Co，Cr，Cu，Fe，Ga，K，Li，Mg，Mn，Na，Ni，Pb组成的以下化学污染物 ，Sr，V，Zn和Ba。

公开(公告)号：US20080279772A1

公开(公告)日：2008-11-13

申请号：US12118519

申请日：2008-05-09

申请人： Maurits W. GEERLINGS

发明人： Maurits W. GEERLINGS

IPC分类号： A61K51/08

CPC分类号： A61K51/1045 ,  A61K51/1093

摘要： The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.

摘要翻译： 本发明涉及现场定向治疗领域。 更具体地，本发明涉及定点放射治疗，并且提供了放射性缀合物的生产方法和用于放射免疫治疗的装置。 该方法，共轭物和装置可以实现，而不需要放射性屏蔽和/或气密设施。 没有这些限制，本发明在患者的床侧提供了一种简单且有效的治疗方法。

公开(公告)号：US20240301081A1

公开(公告)日：2024-09-12

申请号：US18632379

申请日：2024-04-11

申请人： ACTINIUM PHARMACEUTICALS, INC.

发明人： Lequn ZHAO ,  Helen KOTANIDES

IPC分类号： C07K16/28 ,  A61K51/10

CPC分类号： C07K16/289 ,  A61K51/1027 ,  C07K2317/565

摘要： Provided are humanized anti-human CD45 antibodies and pharmaceutical compositions including the antibodies.

公开(公告)号：US20240299600A1

公开(公告)日：2024-09-12

申请号：US18044356

申请日：2021-09-07

申请人： ACTINIUM PHARMACEUTICALS, INC.

发明人： Mark Berger

IPC分类号： A61K51/10 ,  A61K9/00 ,  A61K31/635 ,  A61P35/02

CPC分类号： A61K51/1027 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/635 ,  A61P35/02

摘要： Provided are methods for treating acute myeloid leukemia that include administering a regimen of venetoclax and lintuzumab-Ac225, in which (a) the regimen includes a plurality of cycles, each cycle lasting from 28 to 60 days, (b) the regimen includes (i) orally administering venetoclax on days 1 and 2 of the first cycle at a ramp-up dosage, and thereafter orally administering 400 mg of venetoclax daily on days 3-21 of the first cycle and days 1-21 of each subsequent cycle, and (ii) intravenously administering lintuzumab-Ac225 on day 4, 5, 6 or 7 of each cycle at a dose of from 0.1 μCi/kg to 2.0 μCi/kg, and (c) the subject has a peripheral blast burden at or below 1,000 blast cells/μl. Also provided are related methods in which the regimen includes intravenously administering lintuzumab-Ac225 twice during each cycle.

公开(公告)号：US20240158528A1

公开(公告)日：2024-05-16

申请号：US18409151

申请日：2024-01-10

申请人： ACTINIUM PHARMACEUTICALS, INC.

发明人： Mark BERGER ,  Keisha THOMAS ,  Sandesh SETH ,  Dale Lincoln LUDWIG

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K51/10 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07K16/289 ,  A61K35/17 ,  A61K51/1027 ,  A61K51/1096 ,  A61P35/00 ,  A61P37/00 ,  A61K2039/505

摘要： This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.

公开(公告)号：US20230416348A1

公开(公告)日：2023-12-28

申请号：US18323276

申请日：2023-05-24

申请人： ACTINIUM PHARMACEUTICALS, INC.

发明人： GHOLAMREZA HASSANZADEH GHASSABEH ,  STEVE SCHOONOOGHE ,  HELEN KOTANIDES

IPC分类号： C07K16/18 ,  A61K51/10

CPC分类号： C07K16/18 ,  A61K51/1096 ,  A61K51/1018 ,  C07K2317/569 ,  C07K2317/22 ,  C07K2317/92

摘要： Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.

公开(公告)号：US20230390424A1

公开(公告)日：2023-12-07

申请号：US18025849

申请日：2021-09-13

申请人： ACTINIUM PHARMACEUTICALS, INC.

发明人： Dale L. LUDWIG ,  Eileen GEOGHEGAN

IPC分类号： A61K51/10 ,  A61K39/395 ,  A61K31/502 ,  A61K31/454 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00

CPC分类号： A61K51/1096 ,  A61K39/3955 ,  A61K31/502 ,  A61K31/454 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00 ,  A61K2039/505

摘要： Compositions and methods for treating a solid cancer in a subject by administering an effective amount of a radioisotope labeled trophoblast glycoprotein (5T4)-targeting agent are provided. The 5T4-targeting agent may be an antibody against 5T4 labeled with 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 212Bi, 227Th, or 212Pb. The solid cancer may be a 5T4-positive tumor. The effective amount of the radiolabeled 5T4-targeting agent may be a maximum tolerate dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose. The methods may further include administration of additional agents, such as chemotherapeutic agents, immune checkpoint therapies, and/or DNA damage response inhibitors.

公开(公告)号：US20230132400A9

公开(公告)日：2023-04-27

申请号：US16755589

申请日：2018-11-13

申请人： Actinium Pharmaceuticals, Inc.

发明人： Sandesh SETH ,  Keisha THOMAS

IPC分类号： C07K16/28 ,  A61K38/19 ,  A61P35/00 ,  A61K51/10

摘要： Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 are disclosed. One or both of the anti-CD33 and anti-CD38 antibodies may be labeled with a radioisotope. The antibodies may be administered sequentially or simultaneously. Moreover, each antibody may be administered according to a specific dosing schedule, wherein the administration may be sequential (i.e., one antibody dosing schedule is completed before the next antibody dosing schedule is started) or simultaneous.

公开(公告)号：US20220378955A1

公开(公告)日：2022-12-01

申请号：US17761579

申请日：2020-09-17

申请人： Actinium Pharmaceuticals, Inc.

发明人： Dale LUDWIG ,  Sandesh SETH

IPC分类号： A61K51/10 ,  A61K41/00 ,  C07K16/28 ,  A61P35/00 ,  A61P7/00 ,  A61P37/04

摘要： Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.